Sort
10,766 grants matching “checkpoint inhibitor”
Novel Roles of TAZ and YAP in DNA Damage Repair with 3D Genome Organization and the Therapeutic Resistance in Glioblastoma
$439,965Krishna Pl Bhat · Mayo Clinic Arizona · R01 · FY2025 · NS
Metastatic Clonal Heterogeneity and its Impact on Melanoma Therapeutic Resistance
$439,813Willy Hugo · University Of California Los Angeles · R01 · FY2024 · CA
HSP70 and melanoma
$439,502Maureen E Murphy · Wistar Institute · R01 · FY2018 · CA
HSP70 and melanoma
$439,502Maureen E Murphy · Wistar Institute · R01 · FY2017 · CA
HSP70 and melanoma
$439,502Maureen E Murphy · Wistar Institute · R01 · FY2016 · CA
Project 1: Targeting the PD-1 pathway in HCC
$439,497Ahmed Kaseb · University Of Tx Md Anderson Can Ctr · P50 · FY2021 · CA
Mechanisms and Functions of ATR signaling
$439,201David K Cortez · Vanderbilt University · R01 · FY2019 · CA
Targeting TERT in Melanoma
$439,183Jessie Villanueva · Wistar Institute · R01 · FY2017 · CA
Tackling Treg mediated resistance to radiation and anti-PDL1 in HNSCCs
$439,092Sana D Karam · University Of Colorado Denver · R01 · FY2020 · DE
Tackling Treg mediated resistance to radiation and anti-PDL1 in HNSCCs
$439,092Sana D Karam · University Of Colorado Denver · R01 · FY2021 · DE
Tackling Treg mediated resistance to radiation and anti-PDL1 in HNSCCs
$439,092Sana D Karam · University Of Colorado Denver · R01 · FY2019 · DE
Tackling Treg mediated resistance to radiation and anti-PDL1 in HNSCCs
$439,092Sana D Karam · University Of Colorado Denver · R01 · FY2023 · DE
DNA damage response and cancer immunity
$438,804Christopher J. Bakkenist · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA
Mechanisms of liver metastasis and associated resistance to immunotherapy
$438,730Benjamin Izar · Columbia University Health Sciences · R37 · FY2022 · CA
S100A4 mediated immune suppression in GBM
$438,652Kyuson Yun · Methodist Hospital Research Institute · R01 · FY2022 · NS
S100A4 mediated immune suppression in GBM
$438,652Kyuson Yun · Methodist Hospital Research Institute · R01 · FY2023 · NS
Crosslinking conjugates to localize and activate NK cells in glioblastoma
$438,452Benjamin W. Purow · University Of Virginia · R21 · FY2019 · NS
Novel cell therapy approaches for molecularly defined subsets of therapy-resistant melanoma
$438,385Christopher Austin Klebanoff · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA
Vaccine Targeting of RCC Blood Vessels to Promote TME Normalization and Enhance TIL Recruitment
$438,296Walter J Storkus · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA
Adrenergic signaling inhibition to enhance the immunogenicity of the ovarian tumor microenvironment prior to PD-1 checkpoint therapy
$438,076Guillermo N Armaiz-Pena · Ponce School Of Medicine · R21 · FY2020 · CA
Project 3: Demethylation of HPV-associated head and neck cancer to trigger APOBEC synthetic lethality and enhance immune response
$437,838Karen S Anderson · Yale University · P50 · FY2021 · DE
Project 3: Demethylation of HPV-associated head and neck cancer to trigger APOBEC synthetic lethality and enhance immune response
$437,838Karen S Anderson · Yale University · P50 · FY2023 · DE
Post-translational SOX2 modification - a regulatory switch between self-renewal and differentiation in squamous cell carcinoma
$437,810Markus Schober · New York University School Of Medicine · R01 · FY2024 · CA
Targeting HMGA1 Tumor-Stromal Networks in Pancreatic Carcinogenesis
$437,746Linda M S Resar · Johns Hopkins University · R01 · FY2025 · CA
Engineered Ensemble Nanoimmunotherapies for Cancer
$437,707Rohan Fernandes · George Washington University · R37 · FY2024 · CA